Ken Griffin Immunome Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$11.54 - $22.11 $116,553 - $223,311	10,100 Added 77.69%	23,100 $279,000
Q1 2024 May 15, 2024	SELL	$11.01 - $27.34 $13,212 - $32,808	-1,200 Reduced 8.45%	13,000 $320,000
Q4 2023 Feb 14, 2024	SELL	$7.3 - $10.73 $35,040 - $51,504	-4,800 Reduced 25.26%	14,200 $151,000
Q3 2023 Nov 14, 2023	BUY	$6.17 - $9.16 $64,785 - $96,180	10,500 Added 123.53%	19,000 $158,000
Q2 2023 Aug 14, 2023	BUY	$4.7 - $7.91 $11,280 - $18,984	2,400 Added 39.34%	8,500 $67,000
Q1 2023 May 15, 2023	BUY	$3.26 - $5.69 $19,886 - $34,709	6,100 New	6,100 $30,000

115

43.4M

67.2K

65.9K

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $188M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.